Loading...
•
Jun 30, 2021
Celldex Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Celldex reported a total revenue of $3.5 million and a net loss of $13.4 million, or ($0.34) per share, for the second quarter of 2021. The company's cash, cash equivalents and marketable securities were $164.0 million as of June 30, 2021. They raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021.
Reported positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021
Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021
Cash, cash equivalents and marketable securities as of June 30, 2021 were $164.0 million
Total revenue was $3.5 million in the second quarter of 2021
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2021, along with the approximately $270.0 million in net proceeds raised in our July 2021 underwritten public offering of common stock, are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...